Jain Nikunj 4

What Happened

• Jain Nikunj, Principal Accounting Officer at Sangamo Therapeutics (SGMO), was granted a derivative award on 2026-04-01 for 225,000 shares. The Form 4 reports an acquisition at $0.00 (derivative grant), indicating a stock-based award (option/award), not a cash purchase or sale.

Key Details

• Transaction date: 2026-04-01; Form 4 filed: 2026-04-03 (appears timely — filed within two business days).
• Transaction type/code: A — Grant/Award (derivative).
• Quantity and price: 225,000 shares at $0.00; total cash outlay reported = $0.
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: The award is subject to vesting — 1/4 vests on the first anniversary of the grant; the remainder vests in 24 equal monthly installments thereafter, subject to continuous service and the 2018 EIP; acceleration provisions may apply.
• Tax withholding or sale-to-cover: None indicated in the filing.

Context

• This was a grant of a derivative compensation award (per footnote, an option-like grant) that vests over time — not an exercise or a sale. Such grants are common as retention/compensation for executives and do not represent an immediate cash investment or liquidation by the insider.